Nichols Lab

Marc Bolliger, Ph.D.
Staff Scientist

PhD in Natural Sciences from Swiss Federal Institute of Technology Zurich (ETH)Diploma in Natural Sciences from Swiss Federal Institute of Technology Zurich (ETH)

I joined the Parkinson's Institute as a Staff Scientist in summer 2013. My projects focus on identifying the kinases and phosphatases that regulate LRRK2.

I earned my Ph.D. in biochemistry from ETH Zürich in 2001. Under the supervision of Dr. Sergio Gloor I discovered two neuroligin genes encoding cell adhesion proteins localized at the synapse. One of them, neuroligin 4, became the first gene shown to be implicated in autism. While working as a Postdoctoral Fellow in Dr. Peter Sonderegger's lab at University of Zürich, I investigated neurotrypsin, a neuronal protease associated with mental retardation. Based on the analysis of transgenic and knockout mice we succeeded in identifying the substrate of neurotrypsin, namely agrin, and a developmental analysis of these mice demonstrated that this proteolytic event regulates the maturation of the neuromuscular junction. Then I joined Dr. Thomas Südhof's lab at Stanford University to follow up on my graduate work. We identified a novel point mutation in neuroligin 4 in autistic patients and demonstrated that this mutation impairs protein folding. In addition, I screened for ligands of a brain-specific G-protein coupled receptor, and studied its signaling upon binding of these ligands.

Tyler Molitor, Ph.D.
Postdoctoral Fellow / Vivarium Manager

Ph.D. in Microbiology and Molecular Genetics, Medical College of Wisconsin B.A. in Biology, Lawrence University

Dr. Molitor focuses on understanding cellular signaling mechanisms, particularly kinase signaling, that go awry in PD. He employs multitude of disciplines and model systems in order to dissect pathologic signaling events. He started his scientific training during his undergraduate years at Lawrence University working to understand senescence (cellular aging) mechanisms in the marchantia polymorpha under Dr. Nicholas Maravolo PhD. His focus on kinase biology began during his doctoral training at the Medical College of Wisconsin under the renowned virologist Dr. Paula Traktman. He examined the influence of the viral F10 kinase on the life-cycle of the vaccinia virus. This research led to a body of work dissecting the mammalian Vaccinia Related Kinase (VRK) family culminating in two single author papers on the role of VRK1 in nuclear envelope breakdown and tumorigenesis in an orthotopic xenograft model of breast cancer. Since joining the PICC he has been working to understand the contribution of the Leucine Rich Repeat Kinase 2 (LRRK2) in Parkinson’s disease (PD) pathogenesis focusing on targeting the kinase domain as a potential therapeutic. In addition Dr. Molitor is also the Vivarium Manager at the Parkinson’s Institute and Clinical Center (PICC). He directs all facets of our research animal colony from regulatory oversight and personnel management to pre-clinical trial design. He has 10 years of experience working with and developing genetic rodent models of disease. Since his assignment we have expanded our colony to include 7 genetic models of PD in the 3 major genetic contributors to PD: leucine-rich-repeat kinase 2 (LRRK2),alpha-synuclein (SNCA) and glucocerebrosidase (GBA). These multiple models will further our investigation of prospective therapeutic for multiple genetic facets of PD.

Clinic Providers

Kristin Andruska, MD, PhD
Movement Disorders Specialist

Dr. Andruska is a board-certified neurologist who completed her Fellowship in Movement Disorders at Stanford University. She has expertise in the use of botulinum toxin and deep brain stimulation and is committed to the lifelong care of those with Parkinson’s disease and other movement disorders. She completed her Neurology Residency at Washington University in St. Louis, where she also served as the Chief Resident of Education. She was the recipient of the Irwin Levy Prize for Teaching and the Abdullah M. Nassief Award for Neurology.

She attended the University of Minnesota School of Medicine, graduating from its prestigious Medical Scientist Training Program with both an MD and PhD. Her research in neurobiology focused on disease models of spinocerebellar ataxia (SCA1) in the lab of Dr. Harry Orr, a world-renowned researcher credited with discovering the genetic abnormality causing the disease – a seminal discovery that has had wide-reaching impact in our understanding of neurodegenerative disorders. She received her undergraduate degree in Biology from the University of Texas at Austin.

Dr. Andruska also has significant research experience in Parkinson’s disease. While at Washington University, she focused on two important projects. First, analyzing where alpha-synuclein, the major constituent protein of Lewy Bodies, localizes in the brains of people with Parkinson’s. And second, using sophisticated genetic techniques and population analysis, identifying which genetic variants influence Parkinson’s risk, onset, and progression.

Anthony D Mosley, MD
Movement Disorder Specialist

Dr. Anthony D. Mosley is a board certified neurologist devoted to diagnosing and managing patients with Parkinson's disease and other movement disorders.  Dr. Mosley is a respected and exceptional physician focused on advancing our knowledge about movement disorders and improving the care of his patients. He brings a proven track record of patient focused medicine, and believes family and caretakers are an important partner in caring for individuals with Parkinson's disease. Dr. Mosley has expertise in the use of Botulinum toxin and Deep Brain Stimulation.

Prior to joining the Parkinson’s Institute and Clinical Center, Dr. Mosley was with NW Valley Neurology and Parkinson's Care Specialists in Glendale, AZ.  An experienced clinical researcher, he is a leader in the field of movement disorders.  Dr. Mosley is a published medical journal author, he co-wrote The Encyclopedia of Parkinson’s Disease and The A to Z of Parkinson’s Disease and he is an invited speaker at patient education and continuing medical educational events.

Dr. Mosley received his BS from the University of California in Berkeley, California; his MS from Stanford University in Stanford, California; and his MD from the University of California, San Francisco, California. Dr. Mosley completed his neurology residency at the University of California, Los Angeles School of Medicine, California.

If you would like to learn more about Dr. Mosley or schedule a future appointment with him, please contact Angie Valencia at (408) 542-5697.

Deborah Nin, MA
Speech Therapy

Deborah Nin is a nationally recognized member of the American Speech and Hearing Association (ASHA) and licensed in the state of California as a speech language pathologist. She holds a master’s degree in Communication Sciences and Disorders (MA) from the University of Central Florida and a bachelor’s degree in CSD from the University of Florida. Her experience includes skilled nursing rehabilitation for short term and long term patient care. She is enthusiastic about our community at the Parkinson’s Institute!

Mrs. Nin is certified to provide therapy for patients with Parkinson’s Disease with the Lee Silverman Voice Treatment LOUD program. She is a recipient of the ASHA ACE Award for continuing education. Mrs. Nin participates in continuing education specializing in swallowing, voice, aphasia, and other courses related to adults. Mrs. Nin is also Vital Stim certified and a member of the Medical Speech Pathology Council of California. Mrs. Nin conducts one on one assessment sessions to evaluate each patient’s current level of functioning with patient’s individual’s goals at the center of care.

She is excited to facilitate the PD Choir with Paul Price on the first Thursdays of the month. Mrs. Nin is engaged with PD volunteering at the community level. Mrs. Nin is a strong supporter of evidence-based practice for best patient outcomes. She looks forward to meeting you!

Christopher Way, Dr.

Christopher Way, DO is a board certified neurologist specializing in Parkinson’s Disease and Movement Disorders. He received his undergraduate degree from UCLA in Neuroscience, his medical degree from Touro University in Vallejo, CA and completed his residency in Neurology at Kaiser Permanente Los Angeles Medical Center. He went on to complete a 2-year fellowship training in Parkinson’s Disease and Movement Disorders at the Portland VA Medical Center and Oregon Health & Science University in 2018.

Dr. Way is an advanced practitioner in deep brain stimulation programming with both Medtronic and the newer directional St. Jude Infinity systems for the treatment of Parkinson’s disease, essential tremor, and dystonia. He has expertise in botulinum toxin injections with and without EMG guidance for cervical, craniofacial and limb dystonia, blepharospasm and hemifacial spasm, spasticity, and chronic migraine. He has experience in treating rare genetic movement disorders including spinocerebellar ataxias, primary torsion dystonias, myoclonus-dystonia, and neurodegeneration with brain iron accumulation. 

Dr. Way’s passion lies in caring for patients with Parkinson’s disease. His first exposure to Parkinson’s disease was when his was father was diagnosed with PD in his 40’s. Dr. Way’s father was a patient of Dr. James Tetrud at the Parkinson’s Institute in the early 1990’s and his family’s positive experience with the Parkinson’s Institute was a critical factor in his decision to return to the PI as a physician decades later. Dr. Way is committed to the interdisciplinary team based approach to patient care and research that the Parkinson’s Institute is known for.

Dr. Way’s research has focused on blood pressure fluctuations in Parkinson’s disease and the specificity of a radiologic sign known as the ‘hot cross bun’ sign for an atypical form of parkinsonism known as multiple system atrophy.

In his spare time, he enjoys camping, crossfit, snowboarding, and mountain biking. Now that he is back in the Bay Area, he is looking forward to return to the Lake Tahoe ski resorts that he skied when growing up.

Clinical Research

Andres Alvarez-Pinzon, MD, PhD
Director, Clinical Research & Clinical Studies

Dr. Alvarez-Pinzon has devoted his career to developing and providing rigorous, comprehensive, and compassionate care to those with Neurological Disorders. Dr. Alvarez-Pinzon has diverse experience working in the clinical and Biotech research arena and has worked in Academic and global pharmaceutical firms in different roles. He contributed to the establishment and growth of the Neurosciences Clinical research Department for Miami Neurosciences Center at Larkin, South Miami, Fl. During this time, Dr. Alvarez-Pinzon served as a Clinical Research Fellow for Neuro-Oncology and Gamma Knife Radiosurgery Clinical studies for Larking Community Hospital and Cleveland Clinic Florida.

He joined the Parkinson's Institute and Clinical Center in 2017 after spending 3 years on the Faculty of the Department of Public Health and Health Sciences at South University. He spent a two-year working as a Lead for Neurosciences Clinical Research for the Movement Disorders Center, Memory Center and Comprehensive Stroke Center in Tenet Florida Region. While there, he contributed to many clinical studies for Alzheimer’s, Parkinson’s, and Vascular Neurology trials. He has provided consultation or authored publications for many neurological and neurosciences peer review journals, including the American Academy of Neurological Surgeons (AANS). He is a recipient of an American Academy of Neurological and Orthopedic Surgeons 2016 (AANOS) award. The President of Colombia recognized Dr. Alvarez-Pinzon in 2016 for his resolute efforts to provide the best quality of care for patients with neurological disorders and be an exemplary scientific and physician representing for Colombia worldwide.

Dr. Alvarez-Pinzon is a summa cum laude graduate of University El Bosque, Colombia, where he also obtained his MD and MS degrees. He completed his Internship and Medical visitor training program in Neurology at Universita Biomedico Di Roma, Rome, Italy and a PhD training program in Neurosciences/Neuroplasticity at the University of Salamanca, Spain. He accomplished a Clinical Research fellowship at Cleveland Clinic Florida and Neurological Surgery Research Fellowship at Miami Neurosciences Center. His passion for healthcare and life sciences innovation pushed him to pursue an Executive Master Program in Health Care Administration from Florida Atlantic University and an MSc in Biotechnology & Biotech Enterprise at Johns Hopkins University focusing on healthcare management and Translational Medicine.

Board of Directors

Thomas D. Follett

Mr. Follett serves as chair of the board of directors.  He is a graduate from Norte Dame University (BSE), University of Michigan (MSE) and Xavier University (MBA).   He was an engineer with GE designing aircraft engines.  In 1975, he joined Arthur Andersen which evolved into Accenture.  Mr. Follett became a partner in Accenture in 1985 and specialized in manufacturing systems design and installation in high tech industry.  He retired in 2000 after 25 years with Accenture.  Mr. Follett’s other civic work includes serving on the That Man May See as Chair of the Clinic Committee and is a past president of the ALS Association Bay Area Chapter.

Carrolee Barlow, MD, PhD
Chief Executive Officer

Dr. Barlow received her MD from the University of Utah, did a residency in Internal Medicine at The New York Hospital, Cornell Medical Center and a PhD in molecular and developmental biology at the Karrolinska Medical Nobel Institute in Stockholm, Sweden.  She joined the National Institutes of Health and completed medical subspecialty training in the field of endocrinology and a postdoctoral fellowship in neurogenetics at the National Human Genome Research Institute.  She was a faculty member of the Salk Institute in  translational medicine and genetics.  She has been a pharmaceutical executive since 2002, serving as Chief Scientific Officer and Chief Medical Officer of BrainCells, Inc.  Prior to BrainCells, she served as the Director of Molecular Neuroscience and Therapeutic Area Head for Stroke and Neurodegeneration at Merck Research Laboratories.  Her work has been published in many research journals.  

Peter C. Nosler
Vice Chair

Mr. Nosler is known for his collaborative approach to business leadership.  He and two partners started DPR Construction in 1990 and quickly transformed it from one of the fastest growing private companies in the region to one frequently named among the Best Places to Work.  Today, DPR is one of Silicon Valley’s biggest contractors with a client list that includes AT&T, Apple Computer, and Charles Schwab & Co.  Based in Redwood City, DPR focuses on projects for the biotech, pharmaceutical, and semiconductor markets. The employee-owned company completes about 125 major projects per year.  Over the last ten years DPR has been ranked in the top 50 general contractors in the country, has surpassed the billion dollar mark in sales, and has more than 2000 employees nationwide.  Mr. Nosler leads the DPR Foundation and is an active volunteer with the Monterey Bay Aquarium. 

Susan J. Foster

Ms. Foster is a graduate of University of Nebraska (BA) and San Jose State Univeristy (MA).  She is a former Registered Nurse (RN).  She is a Partner with Learning Designs, Inc.  She has served as a marketing director with Alza Pharmaceuticals.   Her civic engagement includes The Stem Cell Advisors, Child Development Inc. and St. Francis High School. 

Ari Chaney, MBA
Board Member

Mr. Chaney has an MBA from the University of Chicago with High Honors, and a BS in Electrical Engineering from Worcester Polytechnic Institute with High Distinction. Most recently, he was the co-founder and CFO of Cellular Research, a genomics company developing a disruptive platform for precision biology research that was acquired by Becton Dickinson in 2015. Prior to building Cellular Research, Mr. Chaney was the Executive Director for Technology Translation for the Biodesign Program at Stanford University. Mr. Chaney is also the President and Founder of Leveraged Restructuring, where he has held Chairman or CEO positions with a number of companies including: Neucel Specialty Cellulose, Monona Wire Corporation, Rapid Rack Industries and Bomar Industries. Earlier in his career he served as Vice President, Supply Chain for Florida Power & Light (FPL), President and CEO of Aladdin Industries and within General Electric, President & GM of Midwest Electric, Plant Manager of the Austintown Products Plant in GE Lighting, and Manager of Corporate Business Development in GE Corporate. He currently serves on the Boards of Stealth Biosciences, 13.8, and The Parkinson’s Institute.

Sheldon Englehorn
Board Member

Sheldon is an entrepreneur who co-founded a life sciences tool company (now part of Thermo Fisher Scientific). He has served as an Alumni  regent of the University of California, and a trustee of the UC San Diego Foundation. An avid surfer, Sheldon is active with the Director’s Cabinet at Scripps Institution of Oceanography and received the Chancellor’s Medal in 2011.  He also serves as a board member of Nature and Culture International - a conservation organization founded by fellow P.I. director, Ivan Gaylor.

Ivan Gayler
Board Observer

Mr. Gayler is a long time real estate developer and founder of Del Mar Partnership.  Mr. Gayler founded Nature and Culture International in 1997.  Nature and Culture International has helped conserve 8.7 million acres of threated habitats in South America.  His work has been recognized with the San Diego Zoo’s Conservation Medal, an honor shared with Jane Goodall and David Attenborough.  

Judith A. Hemberger, PhD, MBA
Board Member

Dr. Hemberger received her PhD in Pharmacology form the University of Missouri, MBA from Rockhurst College and BS from Mount St. Scholastica College. She is the President and CEO of Suvica, a start-up biotech company. She has been a venture partner with Normura Phase 4 Ventures, Interim CEO of Zosano Pharma and Co-Founder, Executive Vice-President and COO, of Pharmion Corporation which was acquired by Celgene in 2008 for $2.7 billon.

Vernon Norviel, J.D.
Board Member

Mr. Norviel is a partner at Wilson Sonsini Goodrich & Rosati, where he leads the patents and innovation counseling practice. Mr. Norviel has three decades of experience in formulating successful strategies for life science companies and the development of their IP programs. He represents a wide variety of companies, as well as venture capital firms, in areas such as therapeutics, diagnostics, nanotechnology, genomics, proteomics, and personalized medicine. In fact, Mr. Norviel's interest in the field of personalized medicine prompted him to become the first attorney to have had his or her entire genome sequenced and made available in a public database. Before joining the firm in 2003, Mr. Norviel was the general counsel and corporate secretary of Perlegen Sciences, Inc., a start-up biotechnology company that scans the entire human genome for important therapeutic and diagnostic products. Previously, as senior vice president and general counsel, he was an early employee of Affymetrix, the biotechnology company that pioneered and developed DNA chip technology. He also had been a partner at Townsend and Townsend and Crew in Palo Alto.Mr. Norviel currently serves as a member of Wilson Sonsini Goodrich & Rosati's Compensation Committee and on the board of the WSGR Foundation, and previously served as a member of the Policy Committee. In addition, he is a lecturer in biotechnology law at UC Berkeley School of Law.

Michael Saign
Board Member

Michael Saign is a Senior Managing Director in Newmark Cornish & Carey’s Silicon Valley office and has consistently been one of the top ranked advisors within the firm. Mr. Saign specializes in developing and implementing customized real estate strategies for a diverse group of clients ranging from high growth startup ventures to global Fortune 500 corporations. In 2015, he directly managed the successful completion of over 1,000,000 square feet of transactions and was ranked within the Top 5 of all Newmark Cornish & Carey agents. Since joining the firm, Mr. Saign has completed over 275 assignments advising technology, life science and professional service companies
Mr. Saign is a native of Silicon Valley and graduate of Boston College where he rowed on the crew team. He currently serves on the Parkinson’s Institute and Clinical Center’s board of directors.

Management Team

Brian Coulter
Chief Executive Officer

Brian is a seasoned Chief Executive Officer with experience in the non-profit sector, for-profit sector, and Federal government. With a formal education in finance, real estate, and business law, as well as, a Masters in Public Administration from the University of Southern California, Los Angeles, he has both academic and practical real-world experience.  He has provided leadership to multiple non-profits as a member of the Board of Directors, often holding the Treasurer position.

With over twenty-one years of experience increasing productivity, efficiency, and accountability, Brian has lead organizations through strong and weak markets. Consistently employing an innovative, can-do management style utilizing financial analysis skills, organizational management, wisdom, and understanding. 

As a Distinguished Alumni of the Finance, Real Estate, and Business Law Department, for California State Polytechnic University, Pomona he has served as Adjunct Professor teaching Corporate Finance to undergraduate students.  Brian is responsible for Finance, Contracting and Government Grants, Facilities, Information Technology and Legal.

Cheryl Gardner
Vice President of Philanthropic Services

Cheryl Gardner’s passion, and her heart, is in the work she’s done with nonprofit organizations throughout her career. Cheryl is a seasoned executive who has worked with nonprofit organizations for nearly 20 years, helping them build and increase revenue streams, establish networks, manage resources, raise awareness, and create and implement solid, enduring programs. In 2010 she launched her own consulting firm, Cheryl Gardner & Associates, which helps nonprofit organizations develop funding and build infrastructure to support their mission.

Clients included: American Bible Society (ABS), Communication Institute/European Leadership Forum, Scriptures in Use (SIU), CASA 50+ Network, and Operation Mobilization (OM).
Cheryl served as Director of Foundations and Strategic Partnerships for Operation Mobilization (OM). Prior to that, she served as interim President/CEO of CASA 50+ Network; Account Executive with the Russ Reid Agency, Vice President of Resource Development for Biblica – International Bible Society; Director of New Membership Development for American Baptist Credit Union (now Christian Community Credit Union); and Director of Government Affairs and Public Relations at Open Doors with Brother Andrew.

Cheryl has traveled globally and worked extensively with international partners across cultures, training and equipping leaders and development staff to effectively communicate their mission to stakeholders and donors. She has worked to advocate for human rights and religious freedom for vulnerable people groups worldwide.

She serves on the Board of Directors Supervisory Committee of Christian Community Credit Union (CCCU) and is a member of the Advisory Board of Purple Hearts, a nonprofit serving victims of domestic violence. She enjoys cycling with her husband, traveling, and cooking/entertaining.

2500 Hospital Drive, Bldg #10, Suite 1 | Mountain View, CA 94040
650.770.0201 main | 650.770.0204 fax (Clinic Secure)